Dandelion Science
Dandelion Science is creating the world’s first Generative Neuromodulation™ platform to treat the brain, aiming to develop targeted therapies for brain disorders by programming network dynamics in the brain. The company is committed to advancing precision therapies for vision and brain disorders through innovative generative technologies and deep scientific expertise, supported by extensive intellectual property and funding from prestigious institutions.
Industries
Nr. of Employees
small (1-50)
Dandelion Science
95 River Street, Suite 5D, Hoboken, NJ, 07030, USA
Patents
Modification of behavior or physical characteristics through visual stimulation
US-12220240-B2
View DetailsModification of behavior or physical characteristics through visual stimulation
US-11484240-B2
View DetailsModification of behavior or physical characteristics through visual stimulation
US-10736526-B2
View Details
Modification of behavior or physical characteristics through visual stimulation
US-12220240-B2
View DetailsModification of behavior or physical characteristics through visual stimulation
US-11484240-B2
View DetailsModification of behavior or physical characteristics through visual stimulation
US-10736526-B2
View DetailsProducts
Generative neuromodulation platform (research platform)
A platform under development that combines generative AI, neuroimaging data, and non-invasive stimulation methods to program and modulate brain network dynamics for therapeutic purposes.
Generative neuromodulation platform (research platform)
A platform under development that combines generative AI, neuroimaging data, and non-invasive stimulation methods to program and modulate brain network dynamics for therapeutic purposes.
Services
Joint research collaborations with academic research centers and neurotechnology organizations to develop and validate neuromodulation therapies.
Joint research collaborations with academic research centers and neurotechnology organizations to develop and validate neuromodulation therapies.
Expertise Areas
- Generative AI for therapy design
- Non-invasive neuromodulation
- Translational neuroscience
- Neuroimaging and image-based analysis
Key Technologies
- Generative artificial intelligence
- Non-invasive neuromodulation techniques
- Precision sensory stimulation
- Advanced neuroimaging
News & Updates
The Wyss Center for Bio and Neuroengineering in Geneva and Dandelion Science are excited to announce a partnership focused on a cutting-edge generative AI neuromodulation platform that could speed the development of safe, non-invasive ways of treating neurodegenerative and neuropsychiatric disorders.
Dandelion Science, a patented US-Swiss Generative Neuromodulation™ company, funded by the NIH and the Swiss Innovation Agency, announces it is the recipient of the Breakthrough Technology Award from The American Macular Degeneration Foundation (AMDF). The approach could transform vision treatment paradigms by shifting the focus from the eye to how the brain processes information.
Dandelion's Programmable Therapeutics™ platform is being developed to support drug development within neurology and psychiatry at the data-processing level, leading to precision outcomes and improved neurofunctional effects. The collaboration with EPFL aims to advance this technology with neuroimaging systems.
Breakthrough Technology Award from The American Macular Degeneration Foundation (AMDF)
Dandelion Science received this award for its innovative approach to vision treatment paradigms, shifting focus from the eye to brain information processing.
The Wyss Center for Bio and Neuroengineering in Geneva and Dandelion Science are excited to announce a partnership focused on a cutting-edge generative AI neuromodulation platform that could speed the development of safe, non-invasive ways of treating neurodegenerative and neuropsychiatric disorders.
Dandelion Science, a patented US-Swiss Generative Neuromodulation™ company, funded by the NIH and the Swiss Innovation Agency, announces it is the recipient of the Breakthrough Technology Award from The American Macular Degeneration Foundation (AMDF). The approach could transform vision treatment paradigms by shifting the focus from the eye to how the brain processes information.
Dandelion's Programmable Therapeutics™ platform is being developed to support drug development within neurology and psychiatry at the data-processing level, leading to precision outcomes and improved neurofunctional effects. The collaboration with EPFL aims to advance this technology with neuroimaging systems.
Breakthrough Technology Award from The American Macular Degeneration Foundation (AMDF)
Dandelion Science received this award for its innovative approach to vision treatment paradigms, shifting focus from the eye to brain information processing.